Only 9.5% of adolescent OUD treatment admissions include medication, vs. 36.4% for adults, leaving youth with the least effective treatment modality

Among adolescents aged 12-17 admitted for opioid use disorder treatment, only 9.5% receive medication-assisted treatment (buprenorphine, methadone, or naltrexone), compared to 36.4% of adult admissions. Fewer than one in three adolescents (30.8%) with past-year opioid use disorder received any substance use treatment at all. Why it matters: adolescents with opioid use disorder receive counseling-only treatment at nearly four times the rate of medication-inclusive treatment despite weaker evidence for counseling alone, so adolescent relapse rates remain high and treatment retention is poor, so adolescent overdose deaths from fentanyl-contaminated drugs have risen sharply (adolescent overdose deaths more than doubled between 2019 and 2021 per KFF data), so a generation of young people with OUD enters adulthood with entrenched addiction and no experience with evidence-based pharmacotherapy, so the long-term burden of untreated adolescent OUD compounds across decades of life. The structural root cause is that buprenorphine is not FDA-approved for patients under 16 (despite being recommended by the Society for Adolescent Health and Medicine), fewer than 23.3% of OUD treatment facilities offer adolescent-tailored programs, and parental consent requirements, pediatrician discomfort with addiction medicine, and insurance restrictions create compounding barriers that effectively exclude adolescents from the standard of care available to adults.